First patients to test promising new pill for Tough-to-Treat prostate cancer
NCT ID NCT06705686
Summary
This is the first study in people to test the safety of a new oral drug called (R)-9bMS for advanced prostate cancer that has spread and no longer responds to standard hormone therapies. The trial will enroll about 40 men to find the safest and most effective dose. The goal is to see if this new drug can help control cancer growth and activate the immune system against the tumor.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC CASTRATION-RESISTANT PROSTATE CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
University of Wisconsin Carbone Cancer Center (UWCCC) - Cancer Connect
RECRUITINGMadison, Wisconsin, 53792, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.